Trevi Therapeutics, Inc. (“Trevi”), a late-stage clinical development
company focused on developing Nalbuphine
ER for chronic pruritus conditions, today announced the closing of a
$15 million senior secured term loan agreement provided by Solar Capital
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.